295 related articles for article (PubMed ID: 25928084)
1. Systems biology analysis reveals NFAT5 as a novel biomarker and master regulator of inflammatory breast cancer.
Remo A; Simeone I; Pancione M; Parcesepe P; Finetti P; Cerulo L; Bensmail H; Birnbaum D; Van Laere SJ; Colantuoni V; Bonetti F; Bertucci F; Manfrin E; Ceccarelli M
J Transl Med; 2015 May; 13():138. PubMed ID: 25928084
[TBL] [Abstract][Full Text] [Related]
2. Wnt (canonical and non canonical) pathways in breast carcinoma with extensive vascular invasion and inflammatory breast carcinoma.
Remo A; Sina S; Barbi S; Simeone I; Insolda J; Parcesepe P; Giordano G; Cerulo L; Ceccarelli M; Fiorica F; Bonetti A; Pancione M; Manfrin E
Pathol Res Pract; 2021 Mar; 219():153347. PubMed ID: 33550148
[TBL] [Abstract][Full Text] [Related]
3. High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes.
Bekhouche I; Finetti P; Adelaïde J; Ferrari A; Tarpin C; Charafe-Jauffret E; Charpin C; Houvenaeghel G; Jacquemier J; Bidaut G; Birnbaum D; Viens P; Chaffanet M; Bertucci F
PLoS One; 2011 Feb; 6(2):e16950. PubMed ID: 21339811
[TBL] [Abstract][Full Text] [Related]
4. Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets.
Van Laere SJ; Ueno NT; Finetti P; Vermeulen P; Lucci A; Robertson FM; Marsan M; Iwamoto T; Krishnamurthy S; Masuda H; van Dam P; Woodward WA; Viens P; Cristofanilli M; Birnbaum D; Dirix L; Reuben JM; Bertucci F
Clin Cancer Res; 2013 Sep; 19(17):4685-96. PubMed ID: 23396049
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival.
Bertucci F; Ueno NT; Finetti P; Vermeulen P; Lucci A; Robertson FM; Marsan M; Iwamoto T; Krishnamurthy S; Masuda H; Van Dam P; Woodward WA; Cristofanilli M; Reuben JM; Dirix L; Viens P; Symmans WF; Birnbaum D; Van Laere SJ
Ann Oncol; 2014 Feb; 25(2):358-65. PubMed ID: 24299959
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity.
Rypens C; Marsan M; Van Berckelaer C; Billiet C; Melis K; Lopez SP; van Dam P; Devi GR; Finetti P; Ueno NT; Bertucci F; Dirix P; Neven P; Vermeulen P; Dirix L; Van Laere SJ
Breast Cancer Res Treat; 2020 Apr; 180(2):385-395. PubMed ID: 32043194
[TBL] [Abstract][Full Text] [Related]
7. Relapse-free survival in breast cancer patients is associated with a gene expression signature characteristic for inflammatory breast cancer.
Van Laere S; Beissbarth T; Van der Auwera I; Van den Eynden G; Trinh XB; Elst H; Van Hummelen P; van Dam P; Van Marck E; Vermeulen P; Dirix L
Clin Cancer Res; 2008 Nov; 14(22):7452-60. PubMed ID: 19010862
[TBL] [Abstract][Full Text] [Related]
8. Identification of genes and critical control proteins associated with inflammatory breast cancer using network controllability.
Wakai R; Ishitsuka M; Kishimoto T; Ochiai T; Nacher JC
PLoS One; 2017; 12(11):e0186353. PubMed ID: 29108005
[TBL] [Abstract][Full Text] [Related]
9. Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding.
Van Laere SJ; Van der Auwera I; Van den Eynden GG; Elst HJ; Weyler J; Harris AL; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3249-56. PubMed ID: 16740744
[TBL] [Abstract][Full Text] [Related]
10. Genomic profiling of inflammatory breast cancer: a review.
Bertucci F; Finetti P; Vermeulen P; Van Dam P; Dirix L; Birnbaum D; Viens P; Van Laere S
Breast; 2014 Oct; 23(5):538-45. PubMed ID: 24998451
[TBL] [Abstract][Full Text] [Related]
11. Genomic and expression analysis of microdissected inflammatory breast cancer.
Woodward WA; Krishnamurthy S; Yamauchi H; El-Zein R; Ogura D; Kitadai E; Niwa S; Cristofanilli M; Vermeulen P; Dirix L; Viens P; van Laere S; Bertucci F; Reuben JM; Ueno NT
Breast Cancer Res Treat; 2013 Apr; 138(3):761-72. PubMed ID: 23568481
[TBL] [Abstract][Full Text] [Related]
12. Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer.
Reddy JP; Atkinson RL; Larson R; Burks JK; Smith D; Debeb BG; Ruffell B; Creighton CJ; Bambhroliya A; Reuben JM; Van Laere SJ; Krishnamurthy S; Symmans WF; Brewster AM; Woodward WA
Breast Cancer Res Treat; 2018 Sep; 171(2):283-293. PubMed ID: 29858753
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy.
Bertucci F; Finetti P; Rougemont J; Charafe-Jauffret E; Nasser V; Loriod B; Camerlo J; Tagett R; Tarpin C; Houvenaeghel G; Nguyen C; Maraninchi D; Jacquemier J; Houlgatte R; Birnbaum D; Viens P
Cancer Res; 2004 Dec; 64(23):8558-65. PubMed ID: 15574762
[TBL] [Abstract][Full Text] [Related]
14. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
Gong Y; Huo L; Liu P; Sneige N; Sun X; Ueno NT; Lucci A; Buchholz TA; Valero V; Cristofanilli M
Cancer; 2011 Dec; 117(24):5476-84. PubMed ID: 21713757
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Characterization of Immune Cell Infiltration Characteristics and Drug Sensitivity Analysis in Inflammatory Breast Cancer Based on Bioinformatic Strategy.
Zhang Z; Wu H; Shen C; Zhou F
Biochem Genet; 2024 Apr; 62(2):1021-1039. PubMed ID: 37517031
[TBL] [Abstract][Full Text] [Related]
16. Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease.
Jansen MP; Sas L; Sieuwerts AM; Van Cauwenberghe C; Ramirez-Ardila D; Look M; Ruigrok-Ritstier K; Finetti P; Bertucci F; Timmermans MM; van Deurzen CH; Martens JW; Simon I; Roepman P; Linn SC; van Dam P; Kok M; Lardon F; Vermeulen PB; Foekens JA; Dirix L; Berns EM; Van Laere S
Mol Oncol; 2015 Jun; 9(6):1218-33. PubMed ID: 25771305
[TBL] [Abstract][Full Text] [Related]
17. Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors.
Hamm CA; Moran D; Rao K; Trusk PB; Pry K; Sausen M; Jones S; Velculescu VE; Cristofanilli M; Bacus S
Mol Cancer Ther; 2016 Jul; 15(7):1746-56. PubMed ID: 27196778
[TBL] [Abstract][Full Text] [Related]
18. Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.
Jhaveri K; Teplinsky E; Silvera D; Valeta-Magara A; Arju R; Giashuddin S; Sarfraz Y; Alexander M; Darvishian F; Levine PH; Hashmi S; Zolfaghari L; Hoffman HJ; Singh B; Goldberg JD; Hochman T; Formenti S; Esteva FJ; Moran MS; Schneider RJ
Clin Breast Cancer; 2016 Apr; 16(2):113-22.e1. PubMed ID: 26774497
[TBL] [Abstract][Full Text] [Related]
19. Gene set analysis of post-lactational mammary gland involution gene signatures in inflammatory and triple-negative breast cancer.
Bambhroliya A; Van Wyhe RD; Kumar S; Debeb BG; Reddy JP; Van Laere S; El-Zein R; Rao A; Woodward WA
PLoS One; 2018; 13(4):e0192689. PubMed ID: 29617367
[TBL] [Abstract][Full Text] [Related]
20. Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer.
Alexander A; Karakas C; Chen X; Carey JP; Yi M; Bondy M; Thompson P; Cheung KL; Ellis IO; Gong Y; Krishnamurthy S; Alvarez RH; Ueno NT; Hunt KK; Keyomarsi K
Oncotarget; 2017 Feb; 8(9):14897-14911. PubMed ID: 28107181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
